Murray Stahl's CRSP Position Overview
Murray Stahl (via Horizon Kinetics Asset Management LLC) currently holds 10,682 shares of CRISPR Therapeutics AG (CRSP) worth $692,300, representing 0.01% of the portfolio. First purchased in 2020-Q1, this long-term strategic position has been held for 23 quarters.
Based on 13F filings, Murray Stahl has maintained a strategic position in CRSP, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2023, adding 5,000 shares. Largest reduction occurred in Q4 2023, reducing 443 shares.
Analysis based on 13F filings available since 2013 Q2
Murray Stahl's CRISPR Therapeutics (CRSP) Holding Value Over Time
Track share changes against reported price movement
Quarterly CRISPR Therapeutics (CRSP) Trades by Murray Stahl
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2020 | +5,125 | New Buy | 5,125 | $42.34 |
| Q2 2020 | +1,000 | Add 19.51% | 6,125 | $73.47 |
| Q1 2023 | +5,000 | Add 81.63% | 11,125 | $45.23 |
| Q4 2023 | -443 | Reduce 3.98% | 10,682 | $62.60 |
| Q3 2024 | -443 | Reduce 4.15% | 10,239 | $46.98 |
| Q4 2024 | +443 | Add 4.33% | 10,682 | $39.36 |
| Q2 2025 | -443 | Reduce 4.15% | 10,239 | $48.64 |
| Q3 2025 | +443 | Add 4.33% | 10,682 | $64.81 |
Murray Stahl's CRISPR Therapeutics Investment FAQs
Murray Stahl first purchased CRISPR Therapeutics AG (CRSP) in Q1 2020, acquiring 5,125 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Murray Stahl has held CRISPR Therapeutics AG (CRSP) for 23 quarters since Q1 2020. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Murray Stahl's largest addition to CRISPR Therapeutics AG (CRSP) was in Q1 2020, adding 5,125 shares worth $217,000. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Murray Stahl's firm, Horizon Kinetics Asset Management LLC, owns 10,682 shares of CRISPR Therapeutics AG (CRSP), valued at approximately $692,300. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, CRISPR Therapeutics AG (CRSP) represents approximately 0.01% of Murray Stahl's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Murray Stahl's peak holding in CRISPR Therapeutics AG (CRSP) was 11,125 shares, as reported at the end of Q1 2023. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.